Geoff Brooke
Founder at ACTINOGEN MEDICAL LIMITED
Net worth: 90 392 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bradford J. Duft | M | - |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 21 years |
David Laurence Becker | M | - |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 21 years |
Colin Richard Green | M | 80 |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 21 years |
Steven G. Gourlay | M | 64 | 3 years | |
Peter Webse | M | 61 | 15 years | |
Ross Dobinson | M | 72 | 26 years | |
Kilian Kelly | M | - | 10 years | |
George Morstyn | M | 73 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | 7 years |
Paul Wotton | M | 63 | 8 years | |
Nicki Vasquez | M | 61 | 1 years | |
Darryl Maher | M | - | 4 years | |
Paul Rolan | M | - | 2 years | |
Anthony Phillips | M | - |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | - |
Mikhail Getman | M | - |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | - |
Joanna Johnson | F | - | 3 years | |
Gregory Collier | M | - |
Prevatex Pty Ltd.
Prevatex Pty Ltd. BiotechnologyHealth Technology Prevatex Pty Ltd. is an Australian company that focuses on restoring optimal gut health. The company is based in Geelong West, Australia. The company address the issue of the loss of important gut microbes due to changes in our modern lifestyle, such as bleaching of fresh foods, antibiotic use, and stress. The company was founded by James A. Campbell and Gregory Collier. | - |
Timothy Oldham | M | - | 11 years | |
Therese Russell | F | - | - | |
Brian Levy | M | 72 |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | - |
Ted Greene | M | 81 |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 21 years |
Jean-Luc Tétard | M | 78 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia.
ChemGenex Pharmaceuticals, Inc.
ChemGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals, Inc. manufactures and develops pharmaceuticals. It develops novel protein, antibody, & small molecule therapeutics in the areas of oncology, obesity, diabetes, and central nervous system disorders. The company is a subsidiary of Chemgenex Pharmaceuticals Ltd. It was founded in 2004 and is headquartered in Menlo Park, CA. | 4 years |
Tracey Sunderland | F | - |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | 18 years |
David Elliot Eisenbud | M | - |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | 13 years |
David Alan Pool | M | - |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | 16 years |
Henry Kenneth Windle | M | - |
Cerylid Biosciences Ltd.
Cerylid Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Cerylid Biosciences Ltd. is an Australian pharmaceutical company that manufactures pharmaceutical products. The private company is based in Richmond, Australia. | - |
James Mervis | M | - |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | - |
James Blair | M | 84 |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | - |
Malcolm McComas | M | 68 | 5 years | |
Michael Kotsanis | M | - | 10 years | |
Janine Rolfe | F | - | 2 years | |
Michael Roberts | M | - | 3 years | |
Cheryl Townsend | F | - | 2 years | |
Mark Hyman | M | - | 4 years | |
Jolanta Airey | M | - | 3 years | |
Mary Harney | F | - |
Cerylid Biosciences Ltd.
Cerylid Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Cerylid Biosciences Ltd. is an Australian pharmaceutical company that manufactures pharmaceutical products. The private company is based in Richmond, Australia. | 24 years |
Christian Toouli | M | - | 7 years | |
Dana Hilt | M | 71 | 1 years | |
Miriam Roesner | F | - | - | |
Donald Brumley | M | - | 3 years | |
Francis John Spurway | M | - |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 17 years |
Tamara Miller | F | - | 7 years | |
William Souter | M | - | - | |
Scott Bannan | M | - |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 17 years |
Felicia Colagrande | F | - | 9 years | |
Pavel Rodyukov | M | - |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | - |
Denise Cosgrove | F | - |
Victorian WorkCover Authority
| 11 years |
Suzanne Lipe | M | - | 5 years | |
Tony Rajic | M | - |
Prevatex Pty Ltd.
Prevatex Pty Ltd. BiotechnologyHealth Technology Prevatex Pty Ltd. is an Australian company that focuses on restoring optimal gut health. The company is based in Geelong West, Australia. The company address the issue of the loss of important gut microbes due to changes in our modern lifestyle, such as bleaching of fresh foods, antibiotic use, and stress. The company was founded by James A. Campbell and Gregory Collier. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Timothy Bateman | M | - | 3 years | |
Ross MacDonald | M | 66 | 10 years | |
Sharon Papworth | F | - | 2 years | |
Deborah Ambrosini | F | 50 | 2 years | |
Ronald C. Kal | M | - |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | - |
David Keast | M | - | 14 years | |
Mark Andrew Killmier | M | - | 2 years | |
Simon Christopher England | M | - | 6 years | |
Brendan de Kauwe | M | 46 | 1 years | |
Daniel Parasiliti | M | - | 1 years | |
Bill Ketelbey | M | - | 7 years | |
Thomas O'Neil | M | 59 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | 2 years |
Anton Uvarov | M | - | 4 years | |
Greg Tweedly | M | - |
Victorian WorkCover Authority
| 9 years |
Stewart Washer | M | 54 | 10 years | |
Patrick Owen Burns | M | 85 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | - |
Julie Cherrington | M | 66 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | 1 years |
Dennis Brown | M | 74 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | 5 years |
Alan R. Morton | M | - | 6 years | |
Donald Santel | M | 62 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | 2 years |
Jason Loveridge | M | 63 | 4 years | |
Simon Green | M | - | 3 years | |
Adam Craig | M | 58 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | 4 years |
Vincent Ruffles | M | - | - | |
Norman Gray | M | - | 2 years | |
Simon Penney | M | - | - | |
Shoshanna Zohar | F | - | 1 years | |
David Krasnostein | M | - |
Victorian WorkCover Authority
| 3 years |
David Atkins | M | - | - | |
Daniel Janney | M | 58 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | 4 years |
Suraj Sanghani | M | - | 1 years | |
Nina Webster | M | - | 5 years | |
Wilhelmus Groenhuysen | M | 66 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | - |
David Alan Zohar | M | - | 14 years | |
Zhukov Pervan | M | - | 14 years | |
Jeffery Bruce Parncutt | M | 73 | 4 years | |
Elana Rubin | F | 66 |
Victorian WorkCover Authority
| 11 years |
Paul Francis Barker | M | - |
Victorian WorkCover Authority
| - |
Martin Frederick Rogers | M | 43 | 2 years | |
Elmar Schnee | M | 65 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | - |
Malcolm James | M | - |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | - |
Thomas DeZAo | M | 66 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | - |
J. Buchi | M | 69 |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | - |
Jeff Carter | M | 66 | 3 years | |
Kate Lingard | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
Australia | 78 | 83.87% |
New Zealand | 13 | 13.98% |
United States | 11 | 11.83% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Geoff Brooke
- Personal Network